1. Introduction {#sec1-molecules-24-00263}
===============

G-quadruplex (G4) is one of the characteristic higher-order structures of non-B DNAs \[[@B1-molecules-24-00263]\]. G4-forming DNA sequences have been found in telomeres, CpG islands, and gene-promoter regions \[[@B2-molecules-24-00263],[@B3-molecules-24-00263],[@B4-molecules-24-00263],[@B5-molecules-24-00263],[@B6-molecules-24-00263],[@B7-molecules-24-00263]\], and play critical roles in many biological processes, including replication \[[@B8-molecules-24-00263],[@B9-molecules-24-00263]\], gene transcription \[[@B10-molecules-24-00263]\], and translation \[[@B11-molecules-24-00263],[@B12-molecules-24-00263],[@B13-molecules-24-00263]\]. Thus, compounds that selectively stabilize G4s are promising tools for investigating those functions, as well as candidate therapeutic agents for diseases related to the G4s. Since the G4 structure consists of two or three G-quartet planes with grooves, most G4 ligands so far reported have targeted the G-quartet or the grooves \[[@B14-molecules-24-00263],[@B15-molecules-24-00263]\]. For example, the G4 ligands TMPyP4 \[[@B16-molecules-24-00263],[@B17-molecules-24-00263]\], PhenDC3 \[[@B18-molecules-24-00263]\], and pyridostatin \[[@B14-molecules-24-00263],[@B19-molecules-24-00263]\] interact with the G-quartet in G4, whereas TOxaPy \[[@B20-molecules-24-00263]\] and distamycin A \[[@B21-molecules-24-00263]\] recognize the groove in telomeric G4.

We have developed a series of macrocyclic hexaoxazoles, called 6OTD \[[@B22-molecules-24-00263]\], as G4 ligands based upon the structure of the natural G4 ligand telomestatin \[[@B23-molecules-24-00263],[@B24-molecules-24-00263]\]. Among these derivatives, we have recently shown that 4,2-L2H2-6OTD \[[@B25-molecules-24-00263]\] and L2G2-2M2EG-6OTD \[[@B26-molecules-24-00263]\], obtained by altering the connectivity of the oxazoles or by introducing side chains into the 6OTD core structure, interact selectively with anti-parallel and parallel-type topologies, respectively. Here, we describe the synthesis of a new series of 6OTD derivatives bearing side chains that recognize both the G-quartet and the grooves of G4. One of these ligands, **5b**, stabilizes telomeric G4 preferentially over the G4-forming DNA sequences of *c-kit* and *K-ras*, due to the interaction of a piperazinylalkyl side chain with the groove of telomeric G4 \[[@B27-molecules-24-00263],[@B28-molecules-24-00263],[@B29-molecules-24-00263],[@B30-molecules-24-00263],[@B31-molecules-24-00263]\]. Selective stabilization of telomeric G4 would lead to the senescence and apoptosis of cancer cells through dissociation of telomeric protective proteins such as TRF2 and POT1 from telomeric DNA \[[@B32-molecules-24-00263],[@B33-molecules-24-00263],[@B34-molecules-24-00263],[@B35-molecules-24-00263],[@B36-molecules-24-00263]\].

2. Results and Discussion {#sec2-molecules-24-00263}
=========================

2.1. Design of 6OTD Derivatives for Targeting Telomeric G4 {#sec2dot1-molecules-24-00263}
----------------------------------------------------------

G-quadruplex structures form a variety of topologies depending upon their sequences, and a promising strategy to design "sequence-dependent" selective ligands \[[@B37-molecules-24-00263],[@B38-molecules-24-00263],[@B39-molecules-24-00263]\] is to target both the G-quartet and the G4 grooves. We previously analyzed the interaction mode of L2H2-6M(2)OTD **1** with telomeric DNA by NMR, which is shown in [Figure 1](#molecules-24-00263-f001){ref-type="fig"}a \[[@B40-molecules-24-00263]\], and found that the core structure of the macrocyclic moiety in 6OTD **1** interacts with the G-quartet of telomeric G4 through a π-π interaction. In addition, the two aminoalkyl side chains in **1** interact with the phosphate backbone of DNA. Notably, the architecture, as shown in [Figure 1](#molecules-24-00263-f001){ref-type="fig"}a, includes an additional potential ligand-binding site, i.e., the groove circled in blue. Thus, based on the structure depicted in [Figure 1](#molecules-24-00263-f001){ref-type="fig"}b, we designed tri-substituted 6OTD **2**, which has an additional side chain at C5 of L2H2-6M(2)OTD **1**. We expected that this modification would increase the affinity for telomeric G4 and the specificity of the interaction. Specifically, we designed three types of novel tri-substituted L2H2-6OTD derivatives **3**--**5**, bearing an aminoethyl group, an aminoethoxyethyl group, and a piperazinyethoxyethyl group at C5 in **2**, respectively, and examined their specific interactions with telomeric DNA, as shown in [Figure 2](#molecules-24-00263-f002){ref-type="fig"}.

2.2. Synthesis of Tri-Substituted 6OTD Derivatives ***3**--**5*** {#sec2dot2-molecules-24-00263}
-----------------------------------------------------------------

We synthesized tri-substituted 6OTD derivatives **3**--**5** as summarized in [Scheme 1](#molecules-24-00263-sch001){ref-type="scheme"} and [Scheme 2](#molecules-24-00263-sch002){ref-type="scheme"}. Firstly, the synthesis of tri-amine **3** was carried out. Briefly, the bis-Boc-protected tri-substituted 6OTD **14** was synthesized from trioxazoles **6** and **8** based upon the procedure developed by our group \[[@B41-molecules-24-00263],[@B42-molecules-24-00263]\]. Then, the two Boc groups in **14** were deprotected with TFA to give tri-amine **3** in 81% yield from **13**. Compounds **4** and **5** were synthesized as follows: The amine **14** was reacted with carboxylic acids **15a** (n = 1) and **15b** (n = 2) bearing an azide functional group in the presence of EDCI and HOBt, and the corresponding amides **16a** and **16b** were obtained in 42% and 39% yields, respectively. After reduction of the azide group in **16** under hydrogen in the presence of Pd/C as a catalyst, the resulting amine **17** was deprotected with TFA to give tri-amines **4a** and **4b** in 94% and 90% yields from **16**, respectively. The tri-substituted L2H2-6OTD derivatives of **5a** and **5b,** bearing an *N*-methylpiperazine-substituted side chain, were synthesized similarly to **4** from amine **14** and carboxylic acids **18a** (n = 1) and **18b** (n = 2).

2.3. Stabilization Abilities of ***3**--**5*** for G4-Forming DNA Sequences by Fluorescence Resonance Energy Transfer (FRET) Melting Analysis {#sec2dot3-molecules-24-00263}
---------------------------------------------------------------------------------------------------------------------------------------------

Next, the abilities of **3**--**5** to stabilize telomere, *c-kit*, and *K-ras* G4-forming DNA sequences were compared with that of L2H2-6M(2)OTD **1** by means of FRET melting assay, with results shown in [Table 1](#molecules-24-00263-t001){ref-type="table"} \[[@B43-molecules-24-00263]\]. In the case of telomeric G4, telo21, the Δ*T*~m~ value was increased by ligands **3**--**5** bearing additional side chains compared with L2H2-6M(2)OTD **1**, except for with **5a**. In regards to other G4-forming DNA sequences, slight increases of Δ*T*~m~ for *c-kit* were observed with ligands **3**, **4a**, and **4b**, while significant decreases were observed with **5a** and **5b**. In the case of *K-ras*, the Δ*T*~m~ values were slightly decreased with ligands **5a** and **5b**, respectively. These results suggest that **5b** interacts selectively with telomeric G4 over the G4-forming DNA sequences of *c-kit* and *K-ras*, among the ligands and DNA sequences we examined.

2.4. Docking Studies of Ligands ***3***, ***4***, and ***5b*** with Telomeric G4 {#sec2dot4-molecules-24-00263}
--------------------------------------------------------------------------------

To gain insight into the differences in the stabilizing abilities of **3**, **4**, and **5b**, docking studies with telomeric G4 were carried out. Since the three topologies of telomeric DNA \[[@B44-molecules-24-00263]\] (i.e., anti-parallel, hybrid, and parallel) are affected by ionic conditions, solvents, and ligands, we first analyzed the telomeric G4 topologies induced by ligands **3**--**5** by means of Circular Dichroism (CD) spectroscopy \[[@B45-molecules-24-00263]\]. As shown in [Figure 3](#molecules-24-00263-f003){ref-type="fig"}, telomeric G4 was induced predominantly into the parallel form in the presence of ligands **3**, **4**, and **5b** under cation-free conditions. On the other hand, in case of ligand **5a**, the telomeric G4 was induced mainly into parallel-type topology, but did not show a single, distinctive spectrum, in contrast to the other ligands \[[@B46-molecules-24-00263]\].

With the CD analysis results in hand, docking studies were carried out between parallel-type telomeric G4 and ligands **3**, **4**, and **5b**. The docking energies between the ligands and parallel-type telomeric G4 were calculated, and the distribution of the energies for the top 100 poses is shown in [Figure 4](#molecules-24-00263-f004){ref-type="fig"} \[[@B47-molecules-24-00263]\]. In these calculations, **5b** mainly showed the lowest-energy docking (ca. −9 to −10.5 kcal/mol) among the ligands tested. The next lowest energy was found for **4b**, followed by **4a**, and **3**, which is consistent with the results of the FRET melting analysis, which were shown in [Table 1](#molecules-24-00263-t001){ref-type="table"}.

Docking models with the lowest energy scores for ligands **3**, **4**, and **5b** are depicted in [Figure 5](#molecules-24-00263-f005){ref-type="fig"}. In every case, the hexaoxazole moiety in the ligands stacks with the G-quartet, and the newly introduced side chain is suggested to interact with the groove in the parallel-type telomeric G4. The two nitrogens of piperazine in the side chain in **5b** were suggested to interact efficiently with the phosphate backbone of DNA, which may contribute to **5b**'s potent stabilizing ability for telomeric DNA, compared to **3** and **4**. In the case of **5a**, the newly introduced side chain may have an inappropriate chain length for binding with the groove, resulting in a weak stabilizing ability for parallel-type telomeric G4.

3. Materials and Methods {#sec3-molecules-24-00263}
========================

3.1. General {#sec3dot1-molecules-24-00263}
------------

Flash chromatography was performed on Silica gel 60 (spherical, particle size 0.040--0.100 mm; Kanto Co., Inc., Tokyo, Japan). Preparative-TLC (PLC) was performed using PLC Silica gel 60 F254 (0.5 mm, Merck Ltd., Darmstadt, Germany). Optical rotations were measured on a JASCO P-2200 polarimeter. ^1^H- and ^13^C-NMR spectra were recorded on JEOL JNM-AL300 (300 MHz), JEOL JNM-ECX 400 (400 MHz), and JEOL JNM-ECA 500 (500 MHz). The spectra were referenced internally according to the residual solvent signals of CDCl~3~ (^1^H-NMR, δ = 7.26 ppm; ^13^C-NMR, δ = 77.0 ppm) and DMSO-*d*~6~ (^1^H-NMR, δ = 2.50 ppm; ^13^C-NMR, δ = 39.5 ppm). Dates for ^1^H-NMR were recorded as follows: Chemical shift (δ, ppm), multiplicity (s, singlet; t, triplet; m, multiplet; br, broad), integration, and coupling constant (Hz). Dates for ^13^C-NMR were reported in terms of chemical shift (δ, ppm). Mass spectra were recorded on a JEOL JMS-T100LC spectrometer with ESI-MS mode, using MeOH as solvent.

3.2. Synthesis Methods {#sec3dot2-molecules-24-00263}
----------------------

Compound **10**: To a solution of trioxazole **6** \[[@B41-molecules-24-00263]\] (1.00 g, 1.36 mmol) in THF-H~2~O (3:1, 80 mL) was added LiOH·H~2~O (85.5 mg, 2.04 mmol) at room temperature, and stirred for 30 min. The reaction was acidified with 3 N HCl to give carboxylic acid **7** as a THF-H~2~O solution, which was used without further purification. To a solution of trioxazole **8** \[[@B42-molecules-24-00263]\] (1.20 g, 1.40 mmol) in MeOH-THF (1:3, 80 mL) was added 10% Pd/C (120 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 10 min. The reaction mixture was filtered through a pad of Celite^®^ (FUJIFILM Wako Pure Chemical Co., Osaka, Japan) and eluted with CHCl~3~-MeOH (9:1). The filtrates were concentrated in vacuo to give an amine **9**, which was used without further purification. To a solution of carboxylic acid **7** (THF-H~2~O) was added NMM (451 µL, 4.08 mmol), DMT-MM (1.12 g, 4.08 mmol), and amine **9**, and the mixture was stirred at room temperature. After being stirred overnight, to the reaction mixture was added H~2~O, and the organic layer was extracted with CHCl~3~, washed with 1.2 N HCl, dried over MgSO~4~, and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column chromatography on silica gel (CHCl~3~:MeOH = 200:1) to give bistrioxazole **10** (1.20 g, 75%, two steps). Spectral data for **10**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = −17.8 (*c* 1.1, CHCl~3~); ^1^H-NMR (400 MHz, CDCl~3~) δ 8.31--8.27 (m, 4H), 8.06 (d, *J* = 8.7 Hz, 1H), 7.26--7.21 (m, 5H), 5.90 (m, 1H), 5.47 (m, 1H), 5.33--5.20 (m, 2H), 5.03--4.94 (m, 3H), 4.66--4.57 (m, 3H), 3.95 (s, 3H), 3.73--3.62 (m, 2H), 3.45 (t, *J* = 6.4 Hz, 2H), 3.10 (br, 4H), 2.71 (s, 3H), 2.26--1.78 (m, 4H), 1.52--1.40 (m, 26H); ^13^C-NMR (100 MHz, CDCl~3~) δ 165.0, 161.1, 160.2, 156.3, 155.9, 155.8, 155.2, 151.2, 150.9, 143.8, 141.1, 139.5, 139.2, 139.1, 136.4, 136.1, 134.1, 132.4, 130.5, 129.5, 128.2, 127.8, 127.6, 126.5, 124.3, 117.7, 78.9, 78.8, 77.2, 66.5, 65.8, 54.5, 52.2, 49.0, 46.7, 40.0, 39.8, 38.7, 33.4, 32.5, 29.3, 28.2, 26.7, 22.7, 22.3, 11.6; HRMS (ESI, M + Na) calcd. for C~56~H~67~N~11~O~17~Na 1188.4614, found 1188.4628.

Compound **11**: To a solution of bistrioxazole **10** (400 mg, 340 µmol) in THF (100 mL) was added morpholine (298 µL, 3.43 mmol) and Pd(PPh~3~)~4~ (118 mg, 100 µmol) at room temperature under argon atmosphere and stirred for 10 min. The reaction mixture was concentrated in vacuo, and the residue was purified by column chromatography on silica gel (CHCl~3~:MeOH = 100:3) to give amine **11** (350 mg, 84%). Spectral data for **11**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = +5.33 (*c* 1.4, CHCl~3~); ^1^H-NMR (400 MHz, CDCl~3~) δ 8.31 (s, 1H), 8.30 (s, 1H), 8.27 (s, 1H), 8.07 (d, *J* = 8.7 Hz, 1H), 7.26--7.22 (m, 7H), 5.50--5.44 (m, 1H), 5.24 (br, 1H), 5.04--4.96 (m, 2H), 4.66 (br, 1H), 4.55 (br, 1H), 4.04 (t, *J* = 6.9 Hz, 2H), 3.95 (s, 3H), 3.75--3.44 (m, 4H), 3.12--3.10 (br, 4H), 2.72 (s, 3H), 2.25--0.86 (m, 30H); ^13^C-NMR (100 MHz, CDCl~3~) δ 166.3, 165.1, 161.2, 160.3, 156.3, 155.9, 155.3, 151.1, 143.8, 141.1, 139.6, 139.2, 136.5, 136.1, 134.3, 130.6, 129.6, 128.3, 128.0, 127.7, 79.0, 78.9, 77.2, 70.5, 66.7, 52.3, 49.9, 46.8, 40.2, 40.0, 38.9, 35.4, 32.6, 29.7, 29.3, 28.3, 26.8, 22.9, 22.7, 11.8; HRMS (ESI, M + Na) calcd. for C~52~H~63~N~11~O~15~Na 1104.4403, found 1104.4370.

Compound **3**: To a solution of **13** (70.0 mg, 66.7 µmol) in MeOH (6 mL) was added 10% Pd/C (50.0 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 10 min. The reaction mixture was filtered through a pad of Celite^®^ and eluted with CHCl~3~-MeOH (9:1). The filtrates were concentrated in vacuo to give amine **14**, which was used without further purification. The amine **14** was dissolved in CH~2~Cl~2~-TFA (10:1, 11 mL), and the resulting solution was stirred at room temperature for 10 min. The reaction mixture was concentrated in vacuo to give **3** (38.7 mg, 81%, two steps). Spectral data for **3**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = +46.1 (*c* 1.1, MeOH); ^1^H-NMR (400 MHz, DMSO-*d*~6~) δ 9.14--9.12 (m, 2H), 8.92--8.90 (m, 2H), 8.33--8.27 (m, 2H), 8.15 (br, 2H), 7.75 (br, 4H), 5.45 (dt, *J* = 12.8, 5.5 Hz, 1H), 5.37 (dt, *J* = 12.8, 5.5 Hz, 1H), 3.75--3.29 (m, 4H), 2.81--2.73 (m, 7H), 2.11--1.88 (m, 4H), 1.54--1.19 (m, 8H); ^13^C-NMR (100 MHz, DMSO-*d*~6~) *δ* 164.4, 162.0, 158.9, 158.8, 158.7, 158.3, 155.7, 155.3, 155.1, 154.6, 151.9, 149.8, 142.5, 142.4, 141.8, 141.1, 136.0, 136.0, 129.7, 128.5, 125.9, 123.8, 118.4, 47.2, 47.1, 36.9, 33.3, 26.7, 23.9, 20.9, 11.5; HRMS (ESI, M + H) calcd. for C~33~H~38~N~11~O~8~ 716.2904, found 716.2918.

Compound **16a**: To a solution of **15a** (10.0 mg, 66.6 µmol) in THF-H~2~O (2:1, 3 mL) was added EDCI (38.0 mg, 200 µmol) and HOBt (27.0 mg, 200 µmol) at room temperature. After stirring for 1 h, to the reaction mixture was added amine **14** (61.0 mg, 66.6 µmol). The mixture was stirred for 24 h and quenched with 1.2 N HCl, and the organic layer was extracted with CHCl~3~, dried over MgSO~4~, and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column chromatography on silica gel (CHCl~3~:MeOH = 80:1) to give **16a** (29.0 mg, 42%). Spectral data for **16a**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = −14.5 (*c* 0.58, CHCl~3~); ^1^H-NMR (300 MHz, DMSO-*d*~6~) δ 9.12 (s, 1H), 9.09 (s, 1H), 8.91 (s, 1H), 8.89 (s, 1H), 8.34-8.27 (m, 2H), 7.98 (t, *J* = 6.2 Hz, 1H), 6.77 (t, *J* = 5.2 Hz, 2H), 5.42 (dt, *J* = 12.4, 7.2 Hz, 1H), 5.32 (dt, *J* = 12.4, 7.2 Hz, 1H), 3.84 (d, *J* = 15.5 Hz, 1H), 3.78 (d, *J* = 15.1 Hz, 1H), 3.61--3.27 (m, 6H), 2.84 (br, 4H), 2.75 (s, 3H), 2.04 (br, 2H), 1.90 (br, 2H), 1.33--1.03 (m, 28H); ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ 169.0, 164.5, 162.5, 158.9, 158.7, 155.7, 155.5, 154.5, 154.3, 152.5, 151.0, 142.5, 142.3, 141.7, 141.0, 136.0, 135.9, 129.8, 128.4, 124.8, 124.6, 79.2, 77.2, 69.7, 69.5, 49.8, 47.4, 47.2, 36.6, 33.5, 33.4, 29.2, 28.2, 26.1, 21.1, 11.5; HRMS (ESI, M + Na) calcd. for C~47~H~58~N~14~O~14~Na 1065.4155, found 1065.4143.

Compound **4a**: To a solution of **16a** (20.0 mg, 19.2 µmol) in MeOH (4 mL) was added 10% Pd/C (20.0 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 30 min. The reaction mixture was filtered through a pad of Celite^®^ and eluted with CHCl~3~-MeOH (9:1). The filtrates were concentrated in vacuo to give amine **17a**, which was used without further purification. The amine **17a** was dissolved in CH~2~Cl~2~-TFA (2:1, 3 mL), and the resulting solution was stirred at room temperature for 10 min. The reaction mixture was concentrated in vacuo to give **4a** (8.90 mg, 57%, two steps). Spectral data for **4a**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = +87.8 (*c* 2.3, MeOH); ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ 9.15 (s, 1H), 9.14 (s, 1H), 8.94 (s, 1H), 8.92 (s, 1H), 8.31 (d, *J* = 7.5 Hz, 1H), 8.28 (d, *J* = 7.5 Hz, 1H), 8.23 (t, *J* = 5.7 Hz, 1H), 7.79 (br, 6H), 5.44 (dt, *J* = 12.6, 7.5 Hz, 1H), 5.34 (dt, *J* = 12.6, 7.5 Hz, 1H), 3.84 (d, *J* = 14.9 Hz, 1H), 3.80 (d, *J* = 15.5 Hz, 1H), 3.62-3.21 (m, 4H), 3.00--2.92 (m, 2H), 2.77--2.73 (m, 7H), 2.09--1.91 (m, 4H), 1.53--1.21 (m, 10H); ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ 169.0, 164.5, 158.9, 158.8, 155.7, 155.6, 155.7, 155.6, 154.6, 154.3, 152.5, 151.2, 142.6, 142.4, 141.9, 141.2, 136.0, 135.9, 129.7, 128.5, 124.7, 124.6, 69.7, 66.9, 47.2, 47.1, 38.6, 36.6, 33.5, 33.4, 26.7, 26.2, 20.9, 11.5; HRMS (ESI, M + Na) calcd. for C~37~H~44~N~12~O~10~Na 839.3201, found 839.3196.

Compound **16b**: To a solution of **15b** (15.0 mg, 77.3 µmol) in THF-H~2~O (4:1, 2.5 mL) was added EDCI (44.6 mg, 230 µmol) and HOBt (31.3 mg, 230 µmol) at room temperature. After stirring for 1 h, to the reaction mixture was added amine **14** (70.0 mg, 77.3 µmol). The mixture was stirred for 24 h and quenched with 1.2 N HCl, and the organic layer was extracted with CHCl~3~, dried over MgSO~4~, and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column chromatography on silica gel (CHCl~3~:MeOH = 80:1) to give **16b** (32.7 mg, 39%). Spectral data for **16b**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = −7.6 (*c* 1.7, CHCl~3~); ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ 9.12 (s, 1H), 9.10 (s, 1H), 8.91 (s, 1H), 8.89 (s, 1H), 8.34--8.28 (m, 2H), 7.91 (t, *J* = 6.3 Hz, 1H), 6.78 (t, *J* = 5.7 Hz, 2H), 5.42 (dt, *J* = 12.6, 7.5 Hz, 1H), 5.32 (dt, *J* = 12.6, 7.5 Hz, 1H), 3.80 (d, *J* = 15.5 Hz, 1H), 3.75 (d, *J* = 14.9 Hz, 1H), 3.61--3.22 (m, 10H), 2.90--2.80 (m, 4H), 2.74 (s, 3H), 2.03 (br, 2H), 1.89 (br, 2H), 1.41--0.85 (m, 28H); ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ 169.3, 164.6, 162.5, 158.9, 158.7, 155.7, 155.5, 154.5, 154.3, 152.5, 151.0, 142.5, 142.3, 141.7, 141.0, 136.0, 135.9, 129.8, 128.4, 124.8, 124.6, 79.2, 77.2, 70.1, 70.0, 69.3, 69.2, 50.0, 47.4, 47.2, 36.6, 33.5, 33.4, 29.2, 28.2, 29.1, 21.1, 21.0, 11.5; HRMS (ESI, M + Na) calcd. for C~49~H~62~N~14~O~15~Na 1109.4417, found 1109.4387.

Compound **4b**: To a solution of **16b** (8.00 mg, 7.35 µmol) in MeOH (1 mL) was added 10% Pd/C (10.0 mg), and the mixture was stirred at room temperature under a hydrogen atmosphere for 10 min. The reaction mixture was filtered through a pad of Celite^®^ and eluted with CHCl~3~-MeOH (9:1). The filtrates were concentrated in vacuo to give amine **17b**, which was used without further purification. The amine **17b** was dissolved in CH~2~Cl~2~-TFA (2:1, 3 mL), and the resulting solution was stirred at room temperature for 10 min. The reaction mixture was concentrated in vacuo to give **4b** (2.03 mg, 32%, 2 steps). Spectral data for **4b**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = +58.2 (*c* 2.1, MeOH); ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ 9.15 (s, 1H), 9.14 (s, 1H), 8.94 (s, 1H), 8.92 (s, 1H), 8.30 (d, *J* = 7.5 Hz, 1H), 8.28 (d, *J* = 8.0 Hz, 1H), 8.07 (br, 1H), 7.76 (br, 6H), 5.44 (dt, *J* = 12.6, 6.9 Hz, 1H), 5.35 (dt, *J* = 12.6, 7.5 Hz, 1H), 3.82--2.63 (m, 19H), 2.09--1.87 (m, 4H), 1.53--1.22 (m, 10H); ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ 169.5, 164.5, 162.4, 159.0, 158.8, 158.4, 158.1, 155.7, 155.6, 154.6, 154.4, 152.6, 151.2, 142.6, 142.4, 141.9, 141.2, 137.4, 136.0, 135.9, 129.7, 128.9, 128.5, 128.2, 125.4, 124.7, 124.6, 69.9, 69.3, 66.7, 47.2, 47.0, 38.6, 36.6, 33.5, 33.4, 26.8, 26.1, 21.1, 21.0, 20.9, 11.6; HRMS (ESI, M + Na) calcd. for C~39~H~48~N~12~O~11~Na 883.3463, found 883.3479.

Compound **19a**: To a solution of **18a** (9.60 mg, 47.6 µmol) in THF-H~2~O (2:1, 3 mL) was added EDCI (27.4 mg, 143 µmol) and HOBt (19.3 mg, 143 µmol) at room temperature. After stirring for 1 h, to the reaction mixture was added amine 14 (43.6 mg, 47.6 µmol). The mixture was stirred for 24 h and quenched with 1.2 N HCl, and the organic layer was extracted with CHCl~3~, dried over MgSO~4~, and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column chromatography on silica gel (CHCl~3~:MeOH = 10:1) to give **19a** (40.0 mg, 76%). Spectral data for **19a**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = −0.25 (*c* 1.0, CHCl~3~); ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ 9.12 (s, 1H), 9.09 (s, 1H), 8.91 (s, 1H), 8.90 (s, 1H), 8.32 (d, *J* = 8.0 Hz, 1H), 8.29 (d, *J* = 7.5 Hz, 1H), 8.12 (t, *J* = 6.3 Hz, 1H), 6.78 (t, *J* = 5.7 Hz, 2H), 5.42 (dt, *J* = 12.6, 7.5 Hz, 1H), 5.31 (dt, *J* = 12.6, 7.5 Hz, 1H), 3.77 (d, *J* = 15.5 Hz, 1H), 3.72 (d, *J* = 14.9 Hz, 1H), 3.62-3.24 (m, 4H), 2.84 (br, 4H), 2.74 (s, 3H), 2.36--1.88 (m, 17H), 1.33--1.03 (m, 28H); ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ 169.7, 164.5, 162.5, 158.9, 158.7, 155.7, 155.5, 154.5, 154.3, 152.5, 151.0, 142.5, 142.3, 141.7, 141.0, 136.1, 136.0, 136.1, 135.9, 129.8, 128.5, 124.8, 124.7, 79.2, 77.3, 70.0, 68.5, 56.9, 54.7, 52.9, 47.4, 47.3, 45.7, 36.6, 33.4, 29.2, 28.2, 26.1, 21.1, 11.6; HRMS (ESI, M + Na) calcd. for C~52~H~69~N~13~O~14~Na 1122.4985, found 1122.4991.

Compound **5a**: To a solution of **19a** (6.70 mg, 6.01 μmol) in CH~2~Cl~2~ (2 mL) was added TFA (1 mL) at room temperature, and the mixture was stirred for 10 min. The reaction mixture was concentrated in vacuo to give **5a** (5.14 mg, 95%). Spectral data for **5a**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = +85.6 (*c* 3.4, MeOH); ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ 9.16 (s, 1H), 9.14 (s, 1H), 8.94 (s, 1H), 8.92 (s, 1H), 8.32 (d, *J* = 7.5 Hz, 1H), 8.30 (d, *J* = 8.0 Hz, 1H), 8.04 (t, *J* = 6.3 Hz, 1H), 7.71 (br, 4H), 5.44 (dt, *J* = 12.6, 6.9 Hz, 1H), 5.34 (dt, *J* = 12.6, 7.5 Hz, 1H), 3.81 (d, *J* = 15.5 Hz, 1H), 3.76 (d, *J* = 14.9 Hz, 1H), 3.62--3.19 (m, 15H), 2.98 (br, 2H), 2.75 (br, 7H), 2.07--1.87 (m, 4H), 1.53--1.23 (m, 10H); ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ 169.1, 164.5, 162.5, 159.0, 158.8, 158.5, 155.7, 155.6, 154.6, 154.4, 152.6, 151.2, 142.6, 142.4, 141.9, 141.2, 137.4, 136.0, 135.9, 129.8, 129.0, 128.5, 128.3, 125.4, 124.8, 124.7, 117.7, 115.3, 69.5, 47.3, 47.1, 38.6, 33.5, 33.4, 26.8, 26.7, 26.0, 21.1, 21.0, 11.5; HRMS (ESI, M + H) calcd. for C~42~H~54~N~13~O~10~ 900.4117, found 900.4098.

Compound **19b**: To a solution of **18b** (9.40 mg, 38.1 µmol) in THF-H~2~O (2:1, 3 mL) was added EDCI (22.0 mg, 114 µmol) and HOBt (15.0 mg, 114 µmol) at room temperature. After stirring for 1 h, to the reaction mixture was added amine **14** (34.9 mg, 38.1 µmol). The mixture was stirred for 24 h and quenched with 1.2 N HCl, and the organic layer was extracted with CHCl~3~, dried over MgSO~4~, and filtered. The filtrates were concentrated in vacuo, and the residue was purified by column chromatography on silica gel (CHCl~3~:MeOH = 10:1) to give **19b** (14.4 mg, 33%). Spectral data for **19b**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = −6.7 (*c* 0.65, CHCl~3~); ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ 9.12 (s, 1H), 9.09 (s, 1H), 8.91 (s, 1H), 8.90 (s, 1H), 8.34-8.28 (m, 2H), 7.95 (t, *J* = 5.7 Hz, 1H), 6.78 (t, *J* = 5.7 Hz, 2H), 5.42 (dt, *J* = 12.6, 7.5 Hz, 1H), 5.32 (dt, *J* = 12.6, 7.5 Hz, 1H), 3.79 (d, *J* = 15.5 Hz, 1H), 3.73 (d, *J* = 15.5 Hz, 1H), 3.60--3.16 (m, 8H), 2.86--2.84 (m, 4H), 2.74 (s, 3H), 2.37--1.88 (m, 17H), 1.33--1.04 (m, 28H); ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ 1 169.9, 165.1, 163.0, 162.8, 159.4, 159.2, 156.2, 156.0, 155.0, 154.8, 153.0, 151.5, 143.0, 142.8, 142.2, 141.5, 136.6, 136.4, 130.3, 129.0, 125.3, 125.1, 79.7, 77.7, 70.5, 70.4, 69.9, 68.7, 57.7, 55.2, 53.5, 47.9, 47.7, 46.3, 37.1, 36.3, 34.0, 33.9, 29.7, 28.7, 26.6, 21.6, 21.5, 12.0; HRMS (ESI, M + Na) calcd. for C~54~H~73~N~13~O~15~Na 1166.5247, found 1166.5238.

Compound **5b**: To a solution of **19b** (14.4 mg, 12.6 μmol) in CH~2~Cl~2~ (2 mL) was added TFA (1 mL) at room temperature, and the mixture was stirred for 10 min. The reaction mixture was concentrated in vacuo to give **5b** (11.2 mg, 94%). Spectral data for **5b**: $\left\lbrack \mathsf{\alpha} \right\rbrack_{D}^{25}$ = +29.7 (*c* 4.4, MeOH); ^1^H-NMR (500 MHz, DMSO-*d*~6~) δ 9.15 (s, 1H), 9.14 (s, 1H), 8.94 (s, 1H), 8.92 (s, 1H), 8.31 (d, *J* = 7.5 Hz, 1H), 8.28 (d, *J* = 7.5 Hz, 1H), 8.02 (br, 1H), 7.73 (br, 4H), 5.45 (dt, *J* = 12.6, 7.5 Hz, 1H), 5.34 (dt, *J* = 12.6, 7.5 Hz, 1H), 3.80 (d, *J* = 15.5 Hz, 1H), 3.76 (d, *J* = 15.5 Hz, 1H), 3.60--3.19 (m, 19H), 2.75 (br, 9H), 2.08--1.87 (m, 4H), 1.53--1.17 (m, 10H); ^13^C-NMR (125 MHz, DMSO-*d*~6~) δ 169.4, 164.5, 162.4, 158.8, 155.7, 152.7, 151.2, 141.9, 141.2, 136.0, 128.9, 128.3, 124.8, 117.7, 115.3, 79.2, 69.9, 69.8, 69.3, 47.2, 47.1, 38.6, 33.5, 33.4, 26.8, 26.7, 26.1, 21.1, 21.0, 20.9, 11.5; HRMS (ESI, M + H) calcd. for C~44~H~58~N~13~O~11~ 944.4379, found 944.4344.

3.3. FRET Melting Analysis {#sec3dot3-molecules-24-00263}
--------------------------

Fluorescence resonance energy transfer (FRET) melting assay was performed with an excitation wavelength of 470--505 nm and a detection wavelength of 523--543 nm using the DNA Engine Option 2 Real-Time Cycler PCR detection system (Biorad, Hercules, CA, USA). The dual fluorescently labeled oligonucleotides were used in this protocol ([Table S1](#app1-molecules-24-00263){ref-type="app"}). The donor fluorophore was 6-carboxyfluorescein (FAM) and the acceptor fluorophore was 6-carboxytetramethylrhodamine (TAMRA). All purified nucleotides (Sigma Genosys, Tokyo, Japan) were dissolved as stock solutions (100 μM) in MilliQ water to be used without further purification. Further dilutions of the oligonucleotides were performed with a 60 mM potassium cacodylate buffer (pH 7.4), and FRET experiments were carried out with a 0.4 μM oligonucleotide solution. Dual-labeled DNA was annealed by heating at 99 °C for 5 min, and then slowly cooled to room temperature. Ligands were prepared as DMSO stock solutions (10 mM) and diluted to 1 mM using DMSO, and then diluted to 100 μM using a 60 mM potassium cacodylate buffer (pH 7.4). Next, the annealed DNA (20 μL, 0.4 μM) and the compound solution (20 μL, 2 μM) were distributed across 96-well plates (Takara), with a total volume of 40 μL, with the labeled oligonucleotide (0.2 μM) and the compound (1.0 μM). The plates were incubated at 25 °C for 12 h. Subsequent experiments used the following temperature procedure in RT-PCR, finishing as follows: 25 °C for 20 min, and then a stepwise increase of 1 °C every minute from 25 °C until 99 °C. During the procedures, we measured the FAM fluorescence after each step. The change in the melting temperature at 1.0 μM compound concentration (*ΔT~m~* (1.0 μM)) was calculated from at least three experiments by subtraction of the blank from the averaged melting temperature of each compound.

3.4. CD Spectrometry {#sec3dot4-molecules-24-00263}
--------------------

Circular Dichroism (CD) spectra were recorded on a J-720 spectropolarimeter (JASCO, Tokyo, Japan), using a quartz cell of 1 mm optical path length and an instrument scanning speed of 500 nm/min with a response time of 1 s, and over a wavelength range of 220--320 nm. The oligonucleotide telo24 used in this protocol ([Table S1](#app1-molecules-24-00263){ref-type="app"}) was dissolved as a 1.0 mM stock solution in MilliQ water, to be used without further purification. Further dilution of the nucleotide was done with a 50 mM Tris-HCl buffer (without ions or with 50 mM KCl) from 1 mM stock solutions, to give a concentration of 10 μM. The solution was annealed by heating at 99 °C for 5 min, and then slowly cooled to room temperature, and then titrated into the oligonucleotide samples up to 5 mol equivalents using ligands, and incubated overnight. Finally, the CD spectra are representative of five averaged scans taken at 25 °C.

3.5. Computational Analysis {#sec3dot5-molecules-24-00263}
---------------------------

For the initial coordinates of compounds **3**, **4**, and **5**, ionization and energy minimization were performed by the OPLS3 force field in the LigPrep Script in the Maestro (Schrödinger, LLC, New York, NY, USA). These minimized structures were employed as input structures for docking simulations. The human telomeric G4 structures with parallel-type topologies (PDB ID: 1KF1 and 3UYH) were refined for docking simulations using constrained energy refinements in the OPLS-AA force field (Schrödinger LLC). Docking simulations were performed using the Glide \[[@B48-molecules-24-00263],[@B49-molecules-24-00263]\] SP docking program (Schrödinger, LLC, New York, NY, USA).

4. Conclusions {#sec4-molecules-24-00263}
==============

In conclusion, we have newly synthesized tri-substituted 6OTD derivatives **3**--**5** by introducing aminoethyl, aminoethoxyethyl, and piperazinyethoxyethyl groups at C5 of L2H2-6M(2)OTD **1**, respectively. Among these ligands, **5b** stabilizes telomeric G4 preferentially over *c-kit* and *K-ras* G4s. Docking studies with parallel-type telomeric G4 revealed that the hexaoxazole moiety of **5b** stacks with the G-quartet of telomeric G4, and the newly introduced side chain efficiently interacts with the groove.

**Sample Availability:** Samples of all compounds are available from the authors.
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![(**a**) Structure of L2H2-6M(2)OTD **1** and its interaction with telomeric G-quadruplex (G4), as elucidated by NMR analysis; (**b**) Structure of tri-substituted macrocyclic hexaoxazole (6OTD) **2**, and its possible interaction with telomeric G4.](molecules-24-00263-g001){#molecules-24-00263-f001}

![Structures of novel 6OTD analogs **3**--**5** targeting the G-quartet and the groove of telomeric G4.](molecules-24-00263-g002){#molecules-24-00263-f002}
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![Synthesis of tri-substituted 6OTDs **4** and **5.**](molecules-24-00263-sch002){#molecules-24-00263-sch002}

![Circular Dichroism (CD) spectra of **3**, **4** and **5** in the presence of telomeric G4.](molecules-24-00263-g003){#molecules-24-00263-f003}

![Distribution of docking energies of the top 100 poses of **3**, **4a**, **4b**, and **5b** with parallel-type telomeric G4.](molecules-24-00263-g004){#molecules-24-00263-f004}

![Docking models of parallel-type telomeric G4 with compounds (**a**) **3**, (**b**,**c**) **4**, and (**d**) **5b**.](molecules-24-00263-g005){#molecules-24-00263-f005}
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###### 

Fluorescence resonance energy transfer (FRET) melting analysis of 6OTDs **3**--**5** (1.0 µM) with G4-forming DNA sequences (0.2 µM) \*.

  DNA       ΔT~m~ Values (°C)                                                       
  --------- ------------------- ------------ ------------ ------------ ------------ ------------
  telo21    18.1 ± 0.0          23.4 ± 0.1   23.5 ± 0.2   24.4 ± 0.5   18.0 ± 0.9   26.2 ± 0.3
  *c-kit*   18.3 ± 0.4          20.8 ± 0.2   19.5 ± 0.3   20.7 ± 0.1   12.9 ± 0.6   12.1 ± 0.3
  *K-ras*   10.3 ± 0.4          13.0 ± 1.0   11.9 ± 0.2   13.5 ± 0.2   9.0 ± 0.2    8.2 ± 0.4
  dsDNA     0.1 ± 0.0           0.0 ± 0.1    0.1 ± 0.0    0.0 ± 0.2    0.0 ± 0.1    0.0 ± 0.1

\* Melting temperatures were calculated from the average and SEM of at least three experiments.
